G7 Vivacit-E/Longevity

Status: Open to recruitment.

Study Description: A global, prospective, multi-centre, non-randomised non-controlled, dual cohort post-market clinical follow-up study.

Objectives: To confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) liners and instrumentation in primary and revision total hip arthroplasty.

Study Start Date: July 2021.

Estimated Study Completion Date: December 2033.

Follow-Up: 10 years follow-up.

Number of Patients: 25 recruited in Bournemouth.

Study Sites: Royal Bournemouth Hospital (United Kingdom)

University Hospital Hvidovre (Denmark)

Zuyderland Hospital (Netherlands)

OCON Hengelo (Netherlands)

Skane University Hospital (Sweden)

University of Utah (United States)

Oregon Health and Science University (United States)

Slocum Center for Orthopedics & Sports Medicine (United States)

South Bend Orthopaedics (United States)

Colorado Joint Replacement (United States)

Duke University Medical Center (United States)

Registry Link: Study Details | G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study | ClinicalTrials.gov